1. Home
  2. IMNN vs SINT Comparison

IMNN vs SINT Comparison

Compare IMNN & SINT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMNN
  • SINT
  • Stock Information
  • Founded
  • IMNN 1982
  • SINT 1996
  • Country
  • IMNN United States
  • SINT United States
  • Employees
  • IMNN N/A
  • SINT N/A
  • Industry
  • IMNN Biotechnology: Pharmaceutical Preparations
  • SINT Medical/Dental Instruments
  • Sector
  • IMNN Health Care
  • SINT Health Care
  • Exchange
  • IMNN Nasdaq
  • SINT Nasdaq
  • Market Cap
  • IMNN 12.9M
  • SINT 11.6M
  • IPO Year
  • IMNN 1985
  • SINT 2014
  • Fundamental
  • Price
  • IMNN $5.33
  • SINT $4.52
  • Analyst Decision
  • IMNN Buy
  • SINT Strong Buy
  • Analyst Count
  • IMNN 2
  • SINT 1
  • Target Price
  • IMNN $182.61
  • SINT $25.00
  • AVG Volume (30 Days)
  • IMNN 153.1K
  • SINT 118.4K
  • Earning Date
  • IMNN 11-06-2025
  • SINT 11-11-2025
  • Dividend Yield
  • IMNN N/A
  • SINT N/A
  • EPS Growth
  • IMNN N/A
  • SINT N/A
  • EPS
  • IMNN N/A
  • SINT N/A
  • Revenue
  • IMNN N/A
  • SINT $1,861,000.00
  • Revenue This Year
  • IMNN N/A
  • SINT N/A
  • Revenue Next Year
  • IMNN N/A
  • SINT $87.50
  • P/E Ratio
  • IMNN N/A
  • SINT N/A
  • Revenue Growth
  • IMNN N/A
  • SINT N/A
  • 52 Week Low
  • IMNN $4.70
  • SINT $1.71
  • 52 Week High
  • IMNN $41.22
  • SINT $8.60
  • Technical
  • Relative Strength Index (RSI)
  • IMNN 47.96
  • SINT 51.41
  • Support Level
  • IMNN $5.04
  • SINT $3.72
  • Resistance Level
  • IMNN $5.55
  • SINT $4.23
  • Average True Range (ATR)
  • IMNN 0.29
  • SINT 0.39
  • MACD
  • IMNN 0.04
  • SINT -0.09
  • Stochastic Oscillator
  • IMNN 70.94
  • SINT 34.33

About IMNN Imunon Inc.

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).

About SINT SiNtx Technologies Inc.

SINTX Technologies Inc is a ceramics company, focused on providing solutions in a variety of biomedical, technical, and antipathogenic applications. It has grown from focusing on the research, development, and commercialization of medical devices manufactured with silicon nitride to becoming a renowed ceramics company engaged in diverse fields, including biomedical, technical, and antipathogenic applications. Its biomedical products are biocompatible, bioactive, antipathogenic, and to have good bone affinity. Spinal implants made from SINTX silicon nitride have been successfully implanted in humans in the US, Europe, Brazil, and Taiwan.

Share on Social Networks: